Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-12-2001 | Paper Report

Is E-cadherin/catenin axis important in grade III ductal carcinomas?

Author: George Skliris

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

Cadherins are glycoproteins, mainly expressed in epithelial cells, that mediate cell-cell adhesion and interact with the interior of the cell via intracellular proteins called catenins. Through interaction with a-actin, a-catenin influences cell motility. ?- and ?-catenins compete with each other for cadherin-binding sites, and the genes encoding them have been proposed as an oncogene and a tumour suppressor gene respectively. Not much is known regarding E-cadherin and catenin expression in breast cancer. Although some studies have linked reduced E-cadherin expression with poor outcome, others have revealed no independent prognostic value. Recent research has found that retained membrane E-cadherin expression was surprisingly associated with shorter survival in a study employing grade I ductal tumours (see Additional information). This study investigated E-cadherin and a-, ?- and ?-catenin protein levels in a cohort of 470 patients diagnosed with grade III ductal carcinomas. …
Literature
1.
go back to reference Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, Barnes DM, Hanby AM: Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol. 2001, 193: 433-441.CrossRefPubMed Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, Barnes DM, Hanby AM: Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol. 2001, 193: 433-441.CrossRefPubMed
Metadata
Title
Is E-cadherin/catenin axis important in grade III ductal carcinomas?
Author
George Skliris
Publication date
01-12-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2001-68463

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine